Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. - Wikidata - thesis-toulmin - TriplyDB

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

http://www.wikidata.org/entity/Q30574939

about

The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.Recent advances in understanding synaptic abnormalities in Rett syndrome Rett Syndrome: Crossing the Threshold to Clinical Translation Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders MECP2 disorders: from the clinic to mice and back Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes MeCP2 Affects Skeletal Muscle Growth and Morphology through Non Cell-Autonomous Mechanisms Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1).Rett Syndrome: Reaching for Clinical Trials Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.Methyl-CpG Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to Inflammatory Stimuli.Microglia as a critical player in both developmental and late-life CNS pathologies.Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window.Repeated insulin-like growth factor 1 treatment in a patient with rett syndrome: a single case study.Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome.β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome Dendritic spine dysgenesis in Rett syndrome.The effect of insulin and insulin-like growth factors on hippocampus- and amygdala-dependent long-term memory formation Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons.The autism-associated gene chromodomain helicase DNA-binding protein 8 (CHD8) regulates noncoding RNAs and autism-related genes Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish.MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy IGF-1 in autosomal dominant cerebellar ataxia - open-label trial.PTP1B: a new therapeutic target for Rett syndrome Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales.Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3 The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.Human Induced Pluripotent Stem Cells Re-Engineer the Study of Neurodevelopmental Disorders.Progress in Rett Syndrome: from discovery to clinical trials Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V Rett syndrome mouse model Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome.Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?Development of the Tailored Rett Intervention and Assessment Longitudinal (TRIAL) database and the Rett Evaluation of Symptoms and Treatments (REST) Questionnaire.MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling.Transcribing the connectome: roles for transcription factors and chromatin regulators in activity-dependent synapse development.Neurotrophic Factors in Mouse Models of Autism Spectrum Disorder: Focus on BDNF and IGF-1.Cigarette Smoke Delays Regeneration of the Olfactory Epithelium in Mice.

P2860

Q26766054-3B4EDE2D-A1A1-44C3-AC98-4B04C989FE83 Q26766164-B6DA47A7-F382-4343-92AF-452AA585FD54 Q26772909-96839F87-C06A-4445-8E33-68671EE814C0 Q26782594-E3F109B8-7CD0-4C43-B6AC-0C77B12E8629 Q26799760-5C7386CD-DBF0-40E1-B00A-EF1B1DBD4947 Q27023257-EC442AE4-7ED8-44B3-ADDD-C435565AC041 Q27304440-2A327E98-6E44-419E-9716-4A07F572A281 Q27312920-E2535C4F-47AF-495E-8988-4EBCAFFE7C31 Q27337778-2BBE1B2F-F67D-4C9E-A8B4-92CC4547E8A9 Q28069589-03DEB76B-D511-4390-A6F0-AB5F7FE4CBB7 Q30009184-2F482F62-1305-4393-8F63-794B01501950 Q30300139-7672C98E-D8FC-4C5E-BCF0-3BEB4AD961DA Q30411278-2B194548-62DD-4690-8EF5-8BBAC732FF90 Q30842578-ED406061-3FA7-4AAF-B049-6E2C73C5E679 Q33702137-A95BEBD4-90C1-4E6A-AEA3-5C9033884271 Q33785978-06EB741C-1121-4B8B-9CB7-FF152E00300B Q33919627-6C4CE7C0-700F-4E0F-8D92-8DED5A45BD78 Q33919634-360B4D23-7A04-4962-AAE9-44AFC79F3657 Q34159085-DD57DFA1-231F-4F17-9442-20D661C8E929 Q34245876-237F510E-6675-415A-A46F-13222CFD05FD Q35593898-D84664AF-FA46-4DED-8FFA-3840A3401E8E Q35753215-CFD94A25-6D29-4819-A3A7-3D9C9A25F677 Q35802879-33315D7D-C0BC-40EE-B543-3020C006DC15 Q35834882-BDB87AA4-ADFC-4D6F-BA2F-4F9045F46C5B Q36003262-2EABCA16-0C62-463E-8E1D-8FE5CD4B9E0E Q36040548-7ADB5FD7-592E-4B7C-9E91-3BF72F3F93E7 Q36063019-4BF2E4D2-420E-45B0-87D6-23BD91EA0CDD Q36594944-AA9F85EB-E2D5-4CD3-951C-04A7BF011741 Q36684355-417E9B19-8DAB-4708-95C5-7894951C553D Q36687971-CBC24C89-D380-4E8D-8038-32E4A19827BC Q37218356-F6B215BF-8BC6-4EF7-BBA4-D6F92B2CE2B3 Q37292336-C0826C66-5AF9-45BF-B9BC-450733F786A0 Q37469694-DAC35042-D400-4FBE-A98D-9C57B62E8ADB Q37558440-F3E85E18-7C51-4DA3-9035-310CB8FE4D51 Q38666640-F053D193-4BF8-4E40-91F2-4AD6F8069E94 Q38715062-C6AE5304-16BE-4A60-AED4-BCAAA43AB2B4 Q38821957-919CC93C-4055-4060-B243-9795BFB6F5FF Q39296630-5D5CEA80-6227-4EDA-9DF8-F2D595BEFE57 Q39334489-7C315E02-3D04-4F88-AB01-E38B19137654 Q42490858-DDBF69F6-9A26-407B-8B7D-9176029B9A94

P2860

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

http://www.wikidata.org/entity/Q30574939

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@ast

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@en

type

label

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@ast

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@en

prefLabel

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@ast

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@en

P1433

Q30574939-DE274778-E223-4D5D-8399-A321F052D620

P1476

Q30574939-36BFC50F-80F9-4A54-B858-80AD046A10EA

P2093

Q30574939-0C80007E-84DA-490C-B137-65C85C99F165

Q30574939-1D875191-77CA-4631-B394-7EE0671AC050

Q30574939-2017586B-7FFD-4CA7-982A-0145FCF8231F

Q30574939-3179365A-D0E3-4EFC-9029-210D76D9573F

Q30574939-4BDCE5E7-B6C0-4FEF-A88B-F86133B91F12

Q30574939-4FCD6E2E-D321-4C81-AF84-69DE431EB004

Q30574939-51079130-CB75-40A1-8DCC-8DD83336ABFB

Q30574939-5C25C883-4FC2-4A5C-97D3-D1A1874E08A6

Q30574939-6108941C-FA77-49F3-A996-9A23C7E602C5

Q30574939-7AB6F1D7-B153-4A7F-9CE6-BAE2FFB3C024

P2860

Q30574939-093A26C4-08CC-4B08-9EA1-0A26F6D2E2A4

Q30574939-098FFADE-60D3-434F-9D9F-7C909CAAEE56

Q30574939-0DF20024-FBC7-4C64-A759-837AC93C0723

Q30574939-178391A5-1324-4021-9A85-14469225EA5C

Q30574939-25F970E2-EF72-4334-BBD2-4CE1BF999A0F

Q30574939-27F7452A-B625-4FD1-9F1D-67EB0F92B401

Q30574939-2E3EA9F5-0767-4819-A96D-9865390C99E3

Q30574939-2FC8D70B-F4D3-4499-85C4-A103CA9083DE

Q30574939-31B81F8B-D847-49BB-8061-20B947C40328

Q30574939-35D3220F-561E-4EE7-93E6-CC31FD8DD4D8

P304

Q30574939-ABCD8E11-57D6-4DEF-9F36-2BE0E2A82155

P31

Q30574939-32BA763F-BAE3-4810-9B0B-E86F87F47775

P356

Q30574939-FF128FD1-05CA-46E5-BF65-55E55491068B

P407

Q30574939-7D482903-691E-40D2-BE38-904DE4A4B8AC

P433

Q30574939-09D032EA-E35E-4F3C-ACAC-115B782ACEC3

P478

Q30574939-75A7875F-8972-4BB0-8308-90C8A13F84A8

P50

Q30574939-70DC3E2A-C2CE-47BD-92BD-51D0BA11FE6F

P577

Q30574939-DEB8131A-D15D-4FE9-B593-55C503029170

P5875

Q30574939-04C8BC8B-3DE4-48E4-BF4B-ED6631D886F7

P698

Q30574939-EB7DCA50-6C11-4853-8F9E-929FA1D33BE2

P921

Q30574939-24F69FA9-64C7-4876-B31E-1A58AC63DD02

P932

Q30574939-D533FC62-86FE-4026-9361-741C21393D13

P356

PNAS.1311141111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Safety, pharmacokinetics, and ...... he treatment of Rett syndrome.

@en

P2093

Alexandra C Walco

http://www.w3.org/2001/XMLSchema#string

Charles A Nelson

http://www.w3.org/2001/XMLSchema#string

Deirdre M Finnegan

http://www.w3.org/2001/XMLSchema#string

Eugenia Ho

http://www.w3.org/2001/XMLSchema#string

Geneva DeGregorio

http://www.w3.org/2001/XMLSchema#string

Heather M O'Leary

http://www.w3.org/2001/XMLSchema#string

Katherine V Barnes

http://www.w3.org/2001/XMLSchema#string

Kush Kapur

http://www.w3.org/2001/XMLSchema#string

Leonard Rappaport

http://www.w3.org/2001/XMLSchema#string

Luis M Pereira

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of fragile X syndrome in mice.

Rett syndrome: revised diagnostic criteria and nomenclature

Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice

MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution

Report of the committee on methods of clinical examination in electroencephalography

Reversal of neurological defects in a mouse model of Rett syndrome

Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function.

Neurodevelopmental effects of insulin-like growth factor signaling.

Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome.

Recent insights into hyperventilation from the study of Rett syndrome.

P304

4596-4601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1311141111

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260761396

http://www.w3.org/2001/XMLSchema#string

P698

24623853

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

3970488

http://www.w3.org/2001/XMLSchema#string